Sms Pharmaceuticals Ltd Stock Price Today (NSE: SMSPHARMA)
Fundamental Score
Sms Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Sms Pharmaceuticals Ltd share price today is ₹385.25, up +0.00% on NSE/BSE as of 20 February 2026. Sms Pharmaceuticals Ltd (SMSPHARMA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.94K (Cr). The 52-week high for SMSPHARMA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 36.26x, SMSPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 11.00% and a debt-to-equity ratio of 0.43.
Sms Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sms Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sms Pharmaceuticals Share Price: A Financial Analysis for Potential Dominance
The pharmaceutical industry, often driven by patent cliffs and new drug approvals, presents unique challenges and opportunities for growth. Today's analysis focuses on Sms Pharmaceuticals share price (₹318.0) and explores its financial standing in relation to its peers, specifically examining its potential for achieving and maintaining industry dominance. This analysis forms part of a larger, 80-parameter fundamental audit of Sms Pharmaceuticals Ltd, verified by Sweta Mishra.
At a Price-to-Earnings (PE) ratio of 36.26, Sms Pharmaceuticals Ltd is trading at a premium compared to some of its competitors, implying investor expectations of future growth. However, when compared to
Mankind Pharma Ltd, a much larger player known for its strong marketing and brand management, the market perception of management quality and execution may differ significantly. This difference in perceived management effectiveness can influence investor confidence and, consequently, share valuation.A crucial element in assessing a company's ability to establish a sustainable competitive advantage, or "moat," is its Return on Capital Employed (ROCE). Sms Pharmaceuticals Ltd's ROCE of 12.19% indicates the efficiency with which the company generates profits from its capital. While a positive figure, its relative strength within the pharmaceutical sector needs further investigation. A higher ROCE, consistently maintained, suggests a stronger moat, potentially derived from proprietary formulations, manufacturing efficiencies, or strong distribution networks. The current ROCE suggests room for improvement to establish a truly formidable barrier to entry for competitors.
Examining the financial health of Sms Pharmaceuticals Ltd in comparison to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd requires a deeper dive into their respective financial statements, specifically looking at revenue growth, profitability margins, and debt levels. These factors, combined with qualitative assessments of pipeline strength and regulatory compliance, will paint a clearer picture of Sms Pharmaceuticals Ltd's long-term prospects and its ability to translate current valuation into sustained performance. This analysis is observational and does not constitute investment advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sms Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SMSPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (17.68%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (76.30%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (23.22%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.70% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (15.88% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (68.06%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-94.11 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 3.16%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (34.65%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Sms Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Sms Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About SMSPHARMA (Sms Pharmaceuticals Ltd)
Sms Pharmaceuticals Ltd (SMSPHARMA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹2.94K (Cr). Sms Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 11.00% and a ROCE of 12.19%. The debt-to-equity ratio stands at 0.43, reflecting the company's capital structure. Investors tracking SMSPHARMA share price can monitor key metrics including P/E ratio, promoter holding of 68.06%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
SMSPHARMA Share Price: Frequently Asked Questions
What is the current share price of Sms Pharmaceuticals Ltd (SMSPHARMA)?
As of 20 Feb 2026, 06:24 am IST, Sms Pharmaceuticals Ltd share price is ₹385.25. The SMSPHARMA stock has a market capitalisation of ₹2.94K (Cr) on NSE/BSE.
Is SMSPHARMA share price Overvalued or Undervalued?
SMSPHARMA share price is currently trading at a P/E ratio of 36.26x, compared to the industry average of 31.77x. Based on this relative valuation, the Sms Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SMSPHARMA share price?
The 52-week high of SMSPHARMA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Sms Pharmaceuticals Ltd share price?
Key factors influencing SMSPHARMA share price include quarterly earnings growth (Sales Growth: 23.22%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sms Pharmaceuticals Ltd a good stock for long-term investment?
Sms Pharmaceuticals Ltd shows a 5-year Profit Growth of 15.88% and an ROE of 11.00%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.43 before investing in SMSPHARMA shares.
How does Sms Pharmaceuticals Ltd compare with its industry peers?
Sms Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare SMSPHARMA share price P/E of 36.26x and ROE of 11.00% against the industry averages to determine competitive standing.
What is the P/E ratio of SMSPHARMA and what does it mean?
SMSPHARMA share price has a P/E ratio of 36.26x compared to the industry average of 31.77x. Investors pay ₹36 for every ₹1 of annual earnings.
How is SMSPHARMA performing according to Bull Run's analysis?
SMSPHARMA has a Bull Run fundamental score of 37.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SMSPHARMA belong to?
SMSPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sms Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for SMSPHARMA?
SMSPHARMA has an ROE of 11.00%, which shows decent profitability but room for improvement. ROE measures how efficiently Sms Pharmaceuticals Ltd generates profits from shareholders capital.
How is SMSPHARMA debt-to-equity ratio and what does it indicate?
SMSPHARMA has a debt-to-equity ratio of 0.43, which indicates moderate leverage that should be monitored.
What is SMSPHARMA dividend yield and is it a good dividend stock?
SMSPHARMA offers a dividend yield of 0.13%, meaning you receive ₹0.13 annual dividend for every ₹100 invested in Sms Pharmaceuticals Ltd shares.
How has SMSPHARMA share price grown over the past 5 years?
SMSPHARMA has achieved 5-year growth rates of: Sales Growth 13.70%, Profit Growth 15.88%, and EPS Growth 14.83%.
What is the promoter holding in SMSPHARMA and why does it matter?
Promoters hold 68.06% of SMSPHARMA shares, with 34.65% pledged. High promoter holding often indicates strong management confidence in Sms Pharmaceuticals Ltd.
What is SMSPHARMA market capitalisation category?
SMSPHARMA has a market capitalisation of ₹2943 crores, placing it in the Small-cap category.
How volatile is SMSPHARMA stock?
SMSPHARMA has a beta of N/A. A beta > 1 suggests the Sms Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SMSPHARMA operating profit margin trend?
SMSPHARMA has a 5-year average Operating Profit Margin (OPM) of 17.68%, indicating the company's operational efficiency.
How is SMSPHARMA quarterly performance?
Recent quarterly performance shows Sms Pharmaceuticals Ltd YoY Sales Growth of 23.22% and YoY Profit Growth of 76.30%.
What is the institutional holding pattern in SMSPHARMA?
SMSPHARMA has FII holding of 0.28% and DII holding of 2.88%. Significant institutional holding often suggests professional confidence in the Sms Pharmaceuticals Ltd stock.